English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Plasma fibrinogen: now also an antidepressant response marker?

MPS-Authors
/persons/resource/persons80435

Martins-de-Souza,  D.
AG Turck, Christoph, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80429

Maccarrone,  G.
AG Turck, Christoph, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80379

Ising,  M.
AG Ising, Marcus, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80401

Kloiber,  S.
AG Lucae, Susanne, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80426

Lucae,  S.
AG Lucae, Susanne, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80372

Holsboer,  F.
Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80561

Turck,  C. W.
AG Turck, Christoph, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

tp2013129a.pdf
(Any fulltext), 338KB

Supplementary Material (public)
There is no public supplementary material available
Citation

Martins-de-Souza, D., Maccarrone, G., Ising, M., Kloiber, S., Lucae, S., Holsboer, F., et al. (2014). Plasma fibrinogen: now also an antidepressant response marker? TRANSLATIONAL PSYCHIATRY, 4: e352. doi:10.1038/tp.2013.129.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0026-B71F-2
Abstract
Major depressive disorder (MDD) is one of the leading causes of global disability. It is a risk factor for noncompliance with medical treatment, with about 40% of patients not responding to currently used antidepressant drugs. The identification and clinical implementation of biomarkers that can indicate the likelihood of treatment response are needed in order to predict which patients will benefit from an antidepressant drug. While analyzing the blood plasma proteome collected from MDD patients before the initiation of antidepressant medication, we observed different fibrinogen alpha (FGA) levels between drug responders and nonresponders. These results were replicated in a second set of patients. Our findings lend further support to a recently identified association between MDD and fibrinogen levels from a large-scale study.